180 Wealth Advisors LLC acquired a new position in shares of Grail, Inc. (NASDAQ:GRAL – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 94,178 shares of the company’s stock, valued at approximately $1,681,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Douglas Lane & Associates LLC bought a new stake in shares of Grail in the fourth quarter valued at about $3,034,000. A. D. Beadell Investment Counsel Inc. bought a new stake in Grail during the 4th quarter valued at $430,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Grail in the 4th quarter worth $26,000.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the company. Wolfe Research began coverage on Grail in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Guggenheim assumed coverage on shares of Grail in a research note on Thursday, October 17th. They set a “neutral” rating for the company. Finally, Morgan Stanley initiated coverage on shares of Grail in a research note on Wednesday, November 27th. They issued an “equal weight” rating and a $16.00 target price for the company.
Grail Price Performance
Shares of NASDAQ:GRAL opened at $18.57 on Tuesday. Grail, Inc. has a 52-week low of $12.33 and a 52-week high of $24.92. The business has a 50-day moving average price of $18.05.
Insiders Place Their Bets
In other Grail news, CFO Aaron Freidin sold 30,452 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $14.02, for a total value of $426,937.04. Following the sale, the chief financial officer now owns 268,277 shares in the company, valued at approximately $3,761,243.54. This represents a 10.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
About Grail
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
- Five stocks we like better than Grail
- Roth IRA Calculator: Calculate Your Potential Returns
- Is a Ford Stock Turnaround on the Horizon?
- Pros And Cons Of Monthly Dividend Stocks
- What PMI Data Says About the NFP Report: 3 Hidden Opportunities
- 3 Stocks to Consider Buying in October
- Cintas: Trade Uncertainty Creates a Buy-the-Dip Opportunity
Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grail, Inc. (NASDAQ:GRAL – Free Report).
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
